Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The VEGF family in cancer and antibody-based strategies for their inhibition Sullivan LA; Brekken RAMAbs 2010[Mar]; 2 (2): 165-75Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in pre-clinical and clinical studies.|*Immunotherapy/trends[MESH]|*Vascular Endothelial Growth Factor A/antagonists & inhibitors[MESH]|Animals[MESH]|Antibodies, Monoclonal/pharmacology/*therapeutic use[MESH]|Antineoplastic Agents/pharmacology/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Humans[MESH]|Neoplasms/*drug therapy/immunology[MESH]|Neovascularization, Pathologic[MESH]|Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors[MESH] |